Literature DB >> 11488636

Interference with CD28, CD80, CD86 or CD152 in collagen-induced arthritis. Limited role of IFN-gamma in anti-B7-mediated suppression of disease.

A C Tellander1, U Pettersson, A Runström, M Andersson, E Michaëlsson.   

Abstract

We have investigated interference with co-stimulation by administering mAbs towards CD28, CD80, CD86, and CD152 in mice immunized for the development of collagen-induced arthritis (CIA). Anti-CD80 and anti-CD86 treatment inhibited disease score and incidence, whereas anti-CD28 treatment led only to a delayed disease onset. Administration of anti-CD152 had no effect. The CII-specific Ab-response was suppressed by the co-stimulatory blockade, with a stronger effect on IgG1 than on IgG2a. The CII-driven T cell proliferation, on the other hand, was not affected. Furthermore, T cells primed in the presence of either anti-B7 or anti-CD28 produced markedly increased amounts of IFN-gamma in response to CII. To investigate whether this increase in IFN-gamma was related to disease suppression, IFN-gamma-deficient mice were immunized with CII, treated with anti-B7 and followed for the development of arthritis. As in the wild-type mice, administration of anti-B7 to IFN-gamma-deficient mice led to a reduced disease incidence and severity as well as reduced anti-CII IgG titers. Collectively, these data stress the importance of co-stimulation for the delivery of B cell help rather than for production of Th1 cytokines. We also demonstrate that the enhanced production of IFN-gamma observed after B7-blockade is not accountable for the anti-B7 mediated inhibition of CIA. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11488636     DOI: 10.1006/jaut.2001.0527

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  8 in total

Review 1.  Co-stimulatory blockade as therapy for rheumatoid arthritis.

Authors:  Sarah L Mackie; Edward M Vital; Frederique Ponchel; Paul Emery
Journal:  Curr Rheumatol Rep       Date:  2005-10       Impact factor: 4.592

Review 2.  B effector cells in rheumatoid arthritis and experimental arthritis.

Authors:  Alison Finnegan; Susan Ashaye; Keith M Hamel
Journal:  Autoimmunity       Date:  2012-04-19       Impact factor: 2.815

Review 3.  Modulating co-stimulation: a rational strategy in the treatment of rheumatoid arthritis?

Authors:  Vivianne Malmström; Christina Trollmo; Lars Klareskog
Journal:  Arthritis Res Ther       Date:  2005-03-16       Impact factor: 5.156

4.  Distinct in vivo roles of CD80 and CD86 in the effector T-cell responses inducing antigen-induced arthritis.

Authors:  Dragana Odobasic; Michelle T Leech; Jin R Xue; Stephen R Holdsworth
Journal:  Immunology       Date:  2008-01-24       Impact factor: 7.397

5.  Synovial Macrophages: Past Life, Current Situation, and Application in Inflammatory Arthritis.

Authors:  Lin-Kun Bai; Ya-Zhen Su; Xue-Xue Wang; Bing Bai; Cheng-Qiang Zhang; Li-Yun Zhang; Gai-Lian Zhang
Journal:  Front Immunol       Date:  2022-07-26       Impact factor: 8.786

6.  Protection against collagen-induced arthritis in mice afforded by the parasitic worm product, ES-62, is associated with restoration of the levels of interleukin-10-producing B cells and reduced plasma cell infiltration of the joints.

Authors:  David T Rodgers; Miguel A Pineda; Mairi A McGrath; Lamyaa Al-Riyami; William Harnett; Margaret M Harnett
Journal:  Immunology       Date:  2014-03       Impact factor: 7.397

7.  T-cell costimulation protects obesity-induced adipose inflammation and insulin resistance.

Authors:  Jixin Zhong; Xiaoquan Rao; Zachary Braunstein; Anne Taylor; Vimal Narula; Jeffrey Hazey; Dean Mikami; Bradley Needleman; Jessica Rutsky; Qinghua Sun; Jeffrey A Deiuliis; Abhay R Satoskar; Sanjay Rajagopalan
Journal:  Diabetes       Date:  2013-11-12       Impact factor: 9.461

8.  Berberine Delays Onset of Collagen-Induced Arthritis through T Cell Suppression.

Authors:  Alexandra A Vita; Hend Aljobaily; David O Lyons; Nicholas A Pullen
Journal:  Int J Mol Sci       Date:  2021-03-29       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.